We recently published 11 Best Cancer Stocks to Buy Right Now. BioNTech SE is one of them.
BioNTech SE (NASDAQ:BNTX), a German biotechnology company, specializes in mRNA-based immunotherapies for cancer and infectious diseases and stands eleventh on our list among the best cancer stocks. Following its global recognition for the COVID-19 vaccine, the company has been expanding its oncology pipeline with personalized cancer immunotherapies, next-generation immunomodulators, and targeted therapies.
In June 2025, BioNTech SE entered a global collaboration with Bristol Myers Squibb (BMS) to co-develop and commercialize BNT327, a bispecific antibody targeting PD-L1 and VEGF-A across multiple solid tumors. The deal, worth up to $11.1 billion, underscores the business’s commitment to advancing oncology beyond its COVID-19 vaccine success.
A scientist in a lab researching the biology of a cancer cell.
BioNTech SE also announced the acquisition of CureVac, a company with proprietary mRNA technology. The company has initiated multiple Phase 1/2 clinical trials with BNT327 and other novel mRNA and antibody-drug conjugate candidates, focusing on combination therapies for breast, lung, colorectal, and other solid tumors. These trials aim to validate synergistic approaches targeting multiple tumor-specific pathways.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
